Microsomal prostaglandin E synthase-1 (mPGES-1) is a key enzyme that couples with cyclooxygenase-2 (COX-2) for the production of PGE 2 . Although COX-2 is known to mediate the growth and progression of several human cancers including hepatocellular carcinoma (HCC), the role of mPGES-1 in hepatocarcinogenesis is not well established. This study provides novel evidence for a key role of mPGES-1 in HCC growth and progression. Forced overexpression of mPGES-1 in two HCC cell lines (Hep3B and Huh7) increased tumor cell growth, clonogenic formation, migration and invasion, whereas knockdown of mPGES-1 inhibited these parameters, in vitro. In a mouse tumor xenograft model, mPGES-1-overexpressed cells formed palpable tumors at earlier time points and developed larger tumors when compared with the control (Po0.01); in contrast, mPGES-1 knockdown delayed tumor development and reduced tumor size (Po0.01). Mechanistically, mPGES-1-induced HCC cell proliferation, invasion and migration involve PGE 2 production and activation of early growth response 1 (EGR1) and b-catenin. Specifically, mPGES-1-derived PGE 2 induces the formation of EGR1-b-catenin complex, which interacts with T-cell factor 4/lymphoid enhancer factor 1 transcription factors and activates the expression of b-catenin downstream genes. Our findings depict a novel crosstalk between mPGES-1/PGE 2 and EGR1/b-catenin signaling that is critical for hepatocarcinogenesis.
Introduction
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver with high mortality and its incidence is rising across the globe (El-Serag and Mason, 1999; El-Serag, 2004; Farazi and DePinho, 2006; Llovet and Bruix, 2008) . The tumor often develops in the background liver with chronic hepatitis and cirrhosis. Consistent with the strong association between chronic inflammation and hepatocarcinogenesis, studies have shown that mediators of inflammation, such as prostaglandins (PGs), have an important role in hepatocarcinogenesis (Wu, 2006) . Increased cyclooxygenase-2 (COX-2) expression has been found in human and animal HCCs, and in dysplastic hepatocytes (Koga et al., 1999; Kondo et al., 1999; Shiota et al., 1999; Bae et al., 2001; Rahman et al., 2001; Leng et al., 2003; Cheng et al., 2004) . In cultured human HCC cells, forced overexpression of COX-2 increases tumor cell growth and invasiveness (Leng et al., 2003; Han et al., 2006) . The COX inhibitors, nonsteroidal anti-inflammatory drugs, inhibit proliferation and induce apoptosis in cultured HCC cells and in animal models of hepatocarcinogenesis (Wu, 2006) , although these inhibitors are known to mediate effects through both COXdependent and -independent mechanisms. These findings provide important preclinical evidence for targeting COX-2 to prevent human hepatic carcinogenesis. However, in light of the increased cardiovascular side effect associated with some COX-2 inhibitors (Couzin, 2004; Vanchieri, 2004; Baron et al., 2006; Grosser et al., 2006) , it is imperative to identify specific molecular targets downstream of COX-2 for effective and safer anti-tumor therapy.
The synthesis of PGs in human cells is controlled by several key enzymes including COXs that convert arachidonic acid to PGH 2 (Smith et al., 2000; Smith and Langenbach, 2001; Kang et al., 2007) and PG E synthase that converts PGH 2 to PGE 2 (Murakami et al., 2000; Stichtenoth et al., 2001; Thoren et al., 2003; Samuelsson et al., 2007) . Similar to COX-2, mPGES-1 is an inducible enzyme that is upregulated during inflammatory conditions and catalyzes the synthesis of PGE 2 under basal as well as inflammatory conditions (Murakami et al., 2000; Stichtenoth et al., 2001; Thoren et al., 2003; Samuelsson et al., 2007) . Elevated expression of mPGES-1 has also been found in several human cancers including HCC (Takii et al., 2007) . Consistent with the documented role of mPGES-1 for PGE 2 synthesis, mPGES-1 knockdown has been shown to inhibit PGE 2 production and reduce tumor cell proliferation and/or invasiveness in several tumor cell types including the Lewis lung carcinoma cells (Kamei et al., 2010) , human prostate cancer cell line DU145 and nonsmall cell lung cancer cell line A549 (Hanaka et al., 2009) . However, in contrast to the established role of COX-2 in the development and progression of human cancers, the role of mPGES-1 in HCC has not been investigated. Given the functional coupling between COX-2 and mPGES-1 for PGE 2 synthesis (Murakami et al., 2000; Murakami and Kudo, 2006) , we postulated that mPGES-1 may represent a potential effective COX-2 downstream target for the chemoprevention and treatment of hepatic cancers. An important advantage of targeting mPGES-1 is to achieve effective anti-tumor therapy without COX-2-inhibitor associated cardiovascular side effect.
Besides PG signaling, Wnt/b-catenin activation has also been implicated in various stages of hepatic tumorigenesis (Satoh et al., 2000; Giles et al., 2003; Merle et al., 2004; Branda and Wands, 2006; Monga, 2006; Zucman-Rossi et al., 2006; Thompson and Monga, 2007) . b-Catenin functions as a transcription cofactor of the T-cell factor/lymphoid enhancer factor (TCF/LEF) family and leads to the activation of Wnt target genes such as c-myc, cyclin D1 and Akt (Tetsu and McCormick, 1999; Moon et al., 2004; Dihlmann et al., 2005; Clevers, 2006; Gordon and Nusse, 2006; Hoppler and Kavanagh, 2007) . In the absence of Wnt ligands, cytoplasmic bcatenin associates in a complex with glycogen synthase kinase-3b (GSK-3b), axin and adenomatosis polyposis coli (APC), in which b-catenin is phosphorylated and targeted for proteosomal degradation. Activation of Wnt signaling causes dissociation of the b-catenin degradation complex, leading to b-catenin accumulation in the nucleus, where it binds TCF/LEF that induce transcription of important downstream target genes implicated in cell proliferation, differentiation and apoptosis (Moon et al., 2004; Clevers, 2006; Gordon and Nusse, 2006; Hoppler and Kavanagh, 2007) .
This study was designed to investigate the biological function and molecular mechanism of mPGES-1 in HCCs. Our data provide novel evidence for a key role of mPGES-1 in human HCC cell growth and progression. We show herein that mPGES-1 enhances HCC cell growth through PGE 2 -mediated activation of early growth response 1 (EGR1) and b-catenin signaling pathway. Overexpression of mPGES-1 or treatment with PGE 2 induces the formation of EGR1-b-catenin complex, which interacts with TCF4/LEF1 transcription factors and activates the expression of b-catenin downstream genes. Our findings in this study disclose a novel mPGES1/PGE 2 -induced activation of EGR1/b-catenin signaling cascade that is crucial for hepatocarcinogenesis.
Results

mPGES-1 enhances HCC growth parameters, in vitro
To determine the effect of mPGES-1 on HCC growth, we constructed human HCC cell lines (Hep3B and Huh7) with forced overexpression or depletion of mPGES-1. Hep3B and Huh7 cells were transfected with mPGES-1 expression vector (pCMV6-AV-GFPmPGES-1), GFP control vector (pCMV6-AC-GFP), mPGES-1 RNAi vector (pGFP-V-RS-mPGES-1) or RNAi control vector (pGFP-V-RS), respectively. Successful alterations of mPGES-1 expression in these stably transfected cells were confirmed by both immunofluorescence and western blotting analyses. As highlighted by immunofluorescence (Figures 1a and b) , the level of GFP-mPGES-1 was increased in cells transfected with the GFP-mPGES-1 expression vector, but decreased in cells transfected with the mPGES-1 RNAi vector. Western blotting analysis showed increased mPGES-1-GFP fusion protein (44 kDa) in mPGES-1-overexpressed cells, and decreased mPGES-1 protein (17 kDa) in mPGES-1 knockdown cells. The synthesis of PGE 2 was significantly increased in mPGES-1-overexpressed cells, but decreased in mPGES-1 knockdown cells. The levels of COX-2, cPGES, mPGE-2 were not significantly altered in cells with mPGES-1 overexpression or knockdown (Supplementary Figure S1 ). Overexpression of mPGES-1 significantly increased the growth of Hep3B and Huh7 cells when compared with the GFP control cells; in contrast, RNAi knockdown of mPGES-1 significantly inhibited tumor cell growth (Figures 1c and d) .
We next performed colony-formation assays in Hep3B and Huh7 cells with altered mPGES-1 expression. As shown in Figures 1e and f, mPGES-1-overexpressed cells showed significantly higher colony formation under the culture plate assay, whereas mPGES-1 knockdown cells showed lower colonyformation efficiency. In Hep3B cells, mPGES-1 overexpression resulted in 38.25 ± 8.4% colony formation, whereas mPGES-1 knockdown led to 4.27±1.1% (Po0.01). In Huh7 cells, mPGES-1 overexpression resulted in 86.68 ± 16.98% colony formation, whereas mPGES-1 knockdown led to 17.64±4.47% colony formation (Po0.01). Similar findings were also observed under the soft-agar assay (Supplementary Figure  S2) . Thus, mPGES-1 signaling enhances colony-formation capacity in HCC cells.
Flowcytometry was next performed to examine the impact of mPGES-1 on cell cycle progression. In Hep3B cells, when mPGES-1 was overexpressed, 52.4% cells entered into S phase with 30.5% of cells staying at G1 phase; in contrast, when mPGES-1 was knocked down, 14.2% cells entered into S phase with 79.6% cells remaining at G1 phase ( Figure 2a and Supplementary Figure S3A ). In Huh7 cells, when mPGES-1 was overexpressed, 62.2% cells entered into S phase with 25.2% of cells staying at G1 phase; when mPGES-1 was knocked down, 11.8% cells entered into S phase with 81.1% cells remaining at G1 phase ( Figure 2b and Supplementary Figure S3B ). These data suggest that mPGES-1 signaling promotes cell cycle progression at G1/S transit. Accordingly, BrdU-labeling experiments showed higher BrdU-positive Hep3B and Huh7 cells when mPGES-1 was overexpressed and lower BrdU-positive cells when mPGES-1 was knocked down (Figures 2c and d) ; these findings indicate that mPGES-1 signaling regulates DNA synthesis in human HCC cells. (Figures 2e  and f) . Under wound-healing assay, the average wound width (mm) were significantly lower in mPGES-1 overexpression group, but higher in mPGES-1 RNAi group (Figures 2g and h ). These findings suggest that mPGES-1 enhances cell invasion, migration and injuryrepair ability in human HCC cells.
mPGES-1 enhances hepatocarcinogenesis, in vivo
To investigate the effect of mPGES-1 on hepatocarcinogenesis in vivo, the Hep3B and Huh7 stable cell lines with altered expression of mPGES-1 were injected In contrast, the time of tumor appearance was prolonged in the mPGES-1 RNAi group compared with the control group (14.21 ± 3.13 days versus 8.54 ± 3.46 days for Hep3B tumors; 16.12 ± 4.07 days versus 9.64 ± 3.11 days for Huh7 tumors) (Po0.01). As shown in Supplementary Figure S4 
mPGES-1 induces b-catenin and EGR1 accumulation in HCC cells
As both PG and Wnt/b-catenin signaling pathways are active in human HCC (Satoh et al., 2000; Branda and Wands, 2006; Monga, 2006; Wu, 2006; Zucman-Rossi et al., 2006) , we examined whether mPGES-1 might regulate b-catenin in our system. Confocal microscopy showed that the nuclear level of b-catenin was increased when mPGES-1 was overexpressed, but decreased when mPGES-1 was knocked down in both Hep3B and Huh7 stable cell lines (Figures 4a and b ). These findings are consistent with the observations that PGE 2 induces b-catenin accumulation in hepatic and colon cancer cells (Castellone et al., 2005; Shao et al., 2005; Lim et al., 2008 Lim et al., , 2009 ). We observed that the level of EGR1 was increased when mPGES-1 was overexpressed, but decreased when mPGES-1 was knocked down (Supplementary Figure S5 ). This finding is noteworthy, given that EGR1 is a key transcription factor involved in the regulation of cell proliferation and apoptosis (Virolle et al., 2001 ; Figure 3 mPGES-1 promotes HCC growth in severe combined immunodeficiency mice. Hep3B and Huh7 cells stably transfected with mPGES-1 expression or small interfering RNA vectors were injected subcutaneously at armpit of severe combined immunodeficiency mice (100 ml cell suspension at a concentration of 1 Â 10 8 cells per ml in phosphate-buffered saline). The mice were monitored for tumor formation (five or six mice for each group), and the tumors were recovered 4 weeks after inoculation (a, Hep3B tumor; b, Huh7 tumor). The wet weight of each tumor and tumor appearance time (days) were determined for each mouse. The photographs of the transplanted tumors are shown in the left panels. The average weight of the xenograft tumors is shown in the mid panels (the data represent mean ± s.e.m., n ¼ 5-6). The average onset time (days) of the xenograft tumors (days) is shown in the right panels (the data represent mean ± s.e.m., n ¼ 5-6).
mPGES-1 promotes HCC growth via activation of EGR1/b-catenin D Lu et al Gitenay, 2009; Lee KH, 2009; Ma et al., 2009; Parra et al., 2009; Thiel et al., 2010) . As both b-catenin and EGR1 are transcription factors/cofactors, we further examined their levels in the nuclei isolated from the Hep3B and Huh7 stable cell lines.
As shown in Figures 4c-h, the nuclear and cytoplasmic levels of b-catenin and EGR1 were increased in mPGES-1-overexpressed cells, but decreased in mPGES-1 knockdown cells. Thus, both b-catenin and EGR1 are downstream targets of mPGES-1. It is noteworthy that the level of b-catenin is inversely correlated with GSK-3b, whereas the level of EGR1 is inversely correlated with sumoylated EGR1 (small ubiquitin-like modifier (SUMO)-EGR1 is not detectable in the cytoplasmic extracts). The inverse correlation between b-catenin and GSK-3b/phosphorylated b-catenin suggests the involvement of GSK-3b in mPGES-1-mediated regulation of b-catenin. This observation is not surprising, given that GSK-3b is known to have an essential role in the canonical Wnt signaltransduction pathway, initiating proteasomal degradation of b-catenin by phosphorylating b-catenin on key residues (Henderson, 2000; Itoh et al., 2005) . Interestingly, GSK-3b can also enter the nucleus, where it binds b-catenin and inhibits b-catenin activity (does not result in b-catenin phosphorylation or degradation) (Diehl et al., 1998; Bijur and Jope, 2001; Morisco et al., 2001; Caspi et al., 2008) . In this study, we found that the level of GSK-3b in the nucleus and cytoplasm was decreased in mPGES-1-overexpressed cells, but increased in In contrast, mPGES-1 knockdown reduces b-catenin with concurrent increase of GSK-3b and phosphorylated b-catenin. Furthermore, mPGES-1 overexpression also increases EGR1 with simultaneous reduction of SUMO-EGR1, whereas mPGES-1 knockdown reduces EGR1, but increases SUMO-EGR1. (e, f) Western blotting using nuclear proteins from Hep3B (e) and Huh7 (f) cells stably transfected with mPGES-1 expression vector or RNAi vector. mPGES-1-overexpressed cells show increased nuclear levels of b-catenin and EGR1, but decreased nuclear levels of GSK-3b and SUMO-EGR1. An opposite pattern was seen in cells with mPGES-1 depletion. (g, h) Western blotting using cytoplasmic proteins from Hep3B (g) and Huh7 (h) cells stably transfected with mPGES-1 expression vector or RNAi vector. mPGES-1 overexpression increases b-catenin with concurrent reduction of GSK-3b. In contrast, mPGES-1 knockdown reduces b-catenin with concurrent increase of GSK-3b. Furthermore, mPGES-1 overexpression also increases EGR1, whereas mPGES-1 knockdown reduces EGR1. SUMO-EGR1 was not detected in cytoplasmic protein.
mPGES-1 promotes HCC growth via activation of EGR1/b-catenin D Lu et al mPGES-1 knockdown cells, suggesting that mPGES-1-initiated signaling prevents GSK-3b nuclear entry (thus, contributing to b-catenin activation).
mPGES-1 regulates b-catenin and EGR1 levels through PGE 2 in HCC cells As mPGES-1 is a key enzyme for PGE 2 synthesis, we examined the effect of PGE 2 on b-catenin and EGR1 signaling molecules. Similar to the upregulation of b-catenin and EGR1 by mPGES-1 overexpression, PGE 2 treatment also increased the level of b-catenin and EGR1 in nuclear proteins and cell lysates (Figure 5a ). Consistent with the documented role of GSK-3b for b-catenin phosphorylation and degradation, we observed that PGE 2 treatment (for 24 h) decreased the levels of GSK-3b and phospho-b-catenin in human HCC cells. In addition, inhibition of PGE 2 signaling by anti-PGE 2 antibody partially prevented mPGES-1-induced increase of b-catenin and EGR1 ( Figure 5b ). Furthermore, anti-PGE 2 antibody treatment also partially prevented mPGES-1-induced b-catenin binding to EGR1, TCF4 and LEF1 ( Figure 5c ). These findings suggest that mPGES-1 activates b-catenin and EGR1 through PGE 2 in human HCC cells. The observation that anti-PGE 2 antibody treatment (for 24 h) partially reverses mPGES-1-mediated reduction of GSK-3b, suggests GSK-3b inhibition by PGE 2 in mPGES-1-induced b-catenin accumulation.
mPGES-1 induces the formation of EGR1-b-catenin binding complex.
The results presented in the above sections suggest that mPGES-1-derived PGE 2 increased the levels of b-catenin and EGR1. However, before the current study, it was not known whether EGR1 could interact with b-catenin in human cells. To investigate this possibility, we carried out immunoprecipitation assays to determine whether b-catenin might bind EGR1 in the nuclear extract isolated from Hep3B and Huh7 stable cell lines. As shown in Figures 6 and 7 , overexpression of mPGES-1 increased nuclear b-catenin association with EGR1, whereas mPGES-1 knockdown decreased such an interaction. In addition, the interaction between b-catenin with TCF4 or LEF1 was also enhanced in mPGES-1-overexpressed cells, but decreased in mPGES-1 knockdown cells. On the other hand, overexpression of GSK-3b inhibited mPGES-1-indued bcatenin association with EGR1 as well as TCF4. Furthermore, we observed that EGR1 overexpression enhanced mPGES-1-induced b-catenin interaction with TCF4 or LEF1, whereas EGR1 knockdown reduced this interaction. However, EGR1 overexpression did not increase b-catenin association with LEF1 in cells with mPGES-1 depletion, suggesting that mPGES-1 is required for EGR1-mediated b-catenin and LEF1 association. Given that the function of EGR1 in cells can be regulated by sumoylation (Yu et al., 2009) , we further determined whether sumoylation of EGR1 is involved in mPGES-1-mediated b-catenin activation in HCC cells. Our data indicate that only non-sumoylated EGR1 (but not sumoylated EGR1) was able to bind b-catenin. Therefore, sumoylated EGR1 is probably not directly involved in mPGES-1-induced b-catenin activation in HCC cells. Taken together, these findings suggest an important role of EGR1 in mPGES-1-mediated b-catenin association with TCF4/LEF1 transcription factors. Huh7 cell line transfected with mPGES-1 expression vector was treated with 10 ng/ml anti-PGE 2 (highly specific for PGE 2 , purchased from Abcam) or the vehicle control (DMSO) for 24 h. The whole-cell lysates or nuclear extracts were obtained for western blotting analysis. (c) Huh7 cell line transfected with mPGES-1 expression vector was treated with 10 ng/ml anti-PGE 2 antibody or vehicle (DMSO) for 24 h. The whole-cell lysates or nuclear extracts were obtained for western blotting analysis. The nuclear extracts were subjected to immunoprecipitation with anti-b-catenin antibody followed by western blotting analysis for EGR1, TCF4, LEF1 and GSK-3b. Nuclear b-catenin was used as input control for immunoprecipitation; b-actin was used as internal control for routine western blotting. IP, immunoprecipitation; WB, western blotting. Figure 8a , mPGES-1 overexpression enhanced the formation of TCF4/LEF1 protein-DNA complex as detected by electrophoretic mobility shift assay, whereas mPGES-1 knockdown reduced this complex. Similarly, DNA pulldown assay also showed that b-catenin association with TCF/LEF oligonucleotide was increased in mPGES-1-overexpressed cells, but decreased in mPGES-1 knockdown cells (Figure 8b ). Furthermore, mPGES-1 overexpression enhanced the interaction between b-catenin and EGR1 on TCF/LEF DNA consensus site, whereas mPGES-1 knockdown reduced this interaction (Figures 8c and 9a) . The association between b-catenin and TCF4 or LEF1 on the TCF/LEF DNA consensus site was also more abundant in mPGES-1-overexpressed cell, but decreased in mPGES-1 knockdown cells (Figures 8d and 9a ). These findings suggest that mPGES-1 signaling increases b-catenin association with EGR1, TCF4 and LEF1, and enhances their DNA-binding ability. The observation that anti-PGE 2 antibody prevented mPGES-1-induced association of b-catenin/EGR1/TCF4/LEF1 to the TCF/LEF DNA consensus site (Figure 9b ) suggests the involvement of PGE 2 in this process.
To further determine the role of EGR1 in mPGES-1-mediated b-catenin binding to TCF/LEF site, we utilized HCC cells with EGR1 overexpression or knockdown for DNA pulldown analysis. As shown in Figures 8e and 9c , mPGES-1-mediated binding of b-catenin to TCF/LEF site was enhanced when EGR1 was overexpressed, but diminished when EGR1 was knocked down. Knockdown of EGR1 also prevented mPGES-1-induced assembly of b-catenin, TCF4 and LEF1 on their DNA consensus site (Figure 9c ). These findings demonstrate an important role of EGR1 in mPGES-1-induced b-catenin activation.
As a complementary approach, we utilized cells with b-catenin overexpression or knockdown for DNA pulldown analysis. As shown in Figure 8f , the binding of EGR1 to TCF/LEF consensus site was increased when mPGES-1 or b-catenin was overexpressed; in contrast, The nuclear extracts were obtained and subjected to immunoprecipitation by using specific antibodies or immunoglobulin G (IgG) as the control, followed by western blotting using specific antibodies as indicated for each panel. The nuclear extracts or whole-cell lysates were also processed for routine western blotting analysis. IP, immunoprecipitation; WB, western blotting. (a) mPGES-1 increased the association between b-catenin and EGR1. Nuclear b-catenin was used as input control for immunoprecipitation. (b) mPGES-1 increases the interaction between b-catenin and TCF4 in the nuclei isolated from Hep3B stable cell lines; the interaction is enhanced by EGR1 overexpression. Nuclear b-catenin was used as input control for immunoprecipitation. (c) mPGES-1 increases the interaction between b-catenin and TCF4 or LEF1 in the nuclei isolated from Hep3B stable cell lines; the interaction is decreased in cells with EGR1 depletion. Nuclear b-catenin was used as input control for immunoprecipitation. (d) mPGES-1 increases b-catenin binding to EGR1, but not SUMO-EGR1. Western blots for SUMO-EGR1 (102 kDa) or EGR1 (82 kDa) were used as input controls.
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EGR1 could not bind to LEF/TCF consensus site when b-catenin was knocked down. The latter observation indicates that EGR1 itself cannot bind to TCF/LEF DNA element and its association with TCF/LEF consensus site is mediated through interaction with the b-catenin protein. Taken together, these findings show that mPGES-1 signaling increases the association of the b-catenin protein complex with the LEF/TCF consensus site in HCC cells and that EGR1 has a critical role in this process.
mPGES-1 increased b-catenin reporter activity
Consistent with the effect of mPGES-1 signaling on b-catenin-protein complex assembly and DNA binding as presented in the above sections, our further experiments revealed that mPGES-1 overexpression increased b-catenin reporter activity, whereas mPGES-1 knockdown inhibited it (Figure 9d ). Moreover, small interfering RNA depletion of EGR1 significantly inhibited mPGES-1-induced TCF/LEF reporter activity; the degree of inhibition appears similar to that induced by b-catenin The nuclear extracts were obtained and subjected to immunoprecipitation by using specific antibodies or immunoglobulin G (IgG) as the control, followed by western blotting using specific antibodies as indicated for each panel. The nuclear extracts or whole-cell lysates were also processed for routine western blotting analysis. IP, immunoprecipitation; WB, western blotting. (a) mPGES-1 increases the association between b-catenin and EGR1 in the nuclei isolated from Huh7 stable cell lines. Nuclear b-catenin was used as input control for immunoprecipitation.
(b) mPGES-1 increases b-catenin interaction with EGR1, TCF4 or LEF1 in Huh7 cell lines. Upper panels: nuclear extracts were obtained from Huh7 cells with or without mPGES-1 overexpression and processed for immunoprecipitation with anti-b-catenin antibody (or IgG as control), followed by western blotting analysis for EGR1 and TCF4. Mid panels: the aforementioned first immunoprecipitates were cleansed with the elution buffer (0.1% Triton X-100, 0.1% SDS, 0.5% bovine serum albumin in phosphatebuffered saline) (40 ml aliquot of first immunoprecipitates was eluted with 750 ml elution buffer and incubated for 50 min at room temperature). The samples were then subjected to repeat immunoprecipitation (second immunoprecipitates) with anti-LEF1 antibody (or IgG as control), followed by western blotting analysis for EGR1 and b-catenin. Lower panels: the aforementioned second immunoprecipitates were cleansed with the elution buffer and subjected to an additional repeat immunoprecipitation (third immunoprecipitate) with anti-TCF4 antibody (or IgG as control), followed by western blotting analysis for EGR1 and b-catenin. 
mPGES-1-mediated HCC cell growth and invasion depends on b-catenin and EGR1 status
We next examined mPGES-1-mediated growth parameters in cells with overexpression or knockdown of bcatenin and EGR1. As shown in Figure 10a , b-catenin knockdown significantly reduced mPGES-1-induced HCC cell growth. In addition, b-catenin knockdown also partially reduced mPGES-1-induced accumulation of S-phase cells, whereas b-catenin overexpression offsets the effect of mPGES-1 (Figure 10b ). These findings suggest a key role of b-catenin in mPGES-1-induced G1/S transition and cell growth. It is noteworthy that knockdown of both b-catenin and EGR1 almost completely abrogated mPGES-1-induced Sphase cell accumulation. In the wound-healing assay, knockdown of b-catenin or EGR1 significantly prevented mPGES-1-induced cell migration and injuryrepair ability (Figure 10c ). Knockdown of both bcatenin and EGR1 more effectively prevented mPGES-1-induced cell migration and injury repair than knockdown of either b-catenin or EGR1 alone. In transwell assays, knockdown of b-catenin or EGR1 significantly prevented mPGES-1-induced cell invasion (Figure 10d ). These data suggest that mPGES-1-mediated cell growth, migration, invasion and cell cycle progression are regulated through b-catenin and EGR1.
The effect of mPGES-1 on b-catenin downstream signaling molecules We further examined the potential effect of mPGES-1 on the b-catenin downstream signaling molecules. As shown in Figure 11 , the expression of b-catenin downstream genes including c-myc, cyclin D1 and Akt are increased in mPGES-1-overexpressed cells, but decreased in mPGES-1-depleted cells. Consistent with the inhibition of p21 WAF/CIP1 and p27 KIP1 by b-catenin pathway (Philipp-Staheli et al., 2002; Saegusa et al., 2004) , the levels of these cyclin-dependent kinase inhibitors were decreased when mPGES-1 was overexpressed, but increased when mPGES-1 was knocked down. These findings reveal that mPGES-1 regulates b-catenin downstream genes in HCC cells.
Discussion
The current study provides both in vitro and in vivo evidences for an important role of mPGES-1 in hepatocarcinogenesis. Our data showed that overexpression of mPGES-1 in HCC cells increased tumor cell growth, invasion, migration and clonogenic-formation mPGES-1 promotes HCC growth via activation of EGR1/b-catenin D Lu et al capacity, whereas knockdown of mPGES-1 reduced these parameters. In the severe combined immunodeficiency mouse tumor xenograft model, mPGES-1 overexpression enhanced tumor growth, whereas mPGES-1 knockdown delayed tumor development and reduced the tumor size. Our further experiments suggest that bcatenin is a key mPGES-1 downstream target in HCC cells; this assertion is based on the following observations: (1) mPGES-1 overexpression increased the nuclear level of b-catenin, whereas mPGES-1 knockdown decreased it; (2) mPGES-1 overexpression increased bcatenin reporter activity, whereas mPGES-1 knockdown inhibited it; (3) mPGES-1 overexpression enhanced bcatenin association with TCF/LEF, whereas mPGES-1 knockdown decreased it; and (4) mPGES-1 overexpression enhanced b-catenin association with TCF/LEF oligonucleotide, whereas mPGES-1 knockdown reduced it. The importance of b-catenin in mPGES-1-mediated HCC cell growth and progression is reflected by the observation that b-catenin knockdown inhibited mPGES-1-induced HCC cell growth, migration, invasion and cell cycle progression.
mPGES-1-mediated PGE 2 biosynthetic pathway has been implicated in the regulation of various physiological and pathophysiological processes (Jakobsson et al., 1999; Murakami et al., 2000; Stichtenoth et al., 2001; Thoren et al., 2003; Murakami and Kudo, 2006; Kapoor et al., 2007; Samuelsson et al., 2007; Kamei et al., 2010) . In this study, several observations indicate the involvement of PGE 2 in mPGES-1-induced activation of EGR1 and b-catenin in human HCC cells: (1) both mPGES-1 overexpression and PGE 2 treatment increased the level of b-catenin and EGR1 with concomitant reduction of GSK-3b and phospho-b-catenin; (2) pretreatment of human HCC cells with anti-PGE 2 antibody prevented mPGES-1-induced increase of b-catenin and EGR1, as In parallel, GSK-3b can also enter the nucleus, where it binds b-catenin and inhibits b-catenin/TCF-mediated transcription (Diehl et al., 1998; Bijur and Jope, 2001; Morisco et al., 2001; Caspi et al., 2008) . Previous studies have shown that PGE 2 induces b-catenin accumulation in hepatic and colon cancer cells through inhibition of GSK-3b-mediated b-catenin degradation (Castellone et al., 2005; Shao et al., 2005; Lim et al., 2008; Lim et al., 2009 ). In the current study, we provide novel evidence for the involvement of EGR1 in mPGES-1/ PGE 2 -induced b-catenin activation. Our data showed that mPGES-1 overexpression increased b-catenin as well as EGR1 with concomitant reduction of GSK-3b, phophorylated b-catenin and SUMO-EGR1. In contrast, mPGES-1 knockdown reduced b-catenin and EGR1 with simultaneous increase of GSK-3b, phosphorylated b-catenin and SUMO-EGR1. Western blotting analysis using nuclear proteins showed that mPGES-1 overexpression or PGE 2 treatment enhanced b-catenin and EGR1 trafficking from cytoplasm to nucleus, whereas mPGES-1 knockdown or anti-PGE 2 antibody treatment reduced this process. These observations suggest that mPGES-1/PGE 2 signaling activates b-catenin through regulation of EGR1 as well as GSK-3b.
EGR1 is emerging as an important regulator of carcinogenesis (Virolle et al., 2001; Gitenay, 2009; Lee KH, 2009; Ma et al., 2009; Parra et al., 2009; Thiel et al., 2010) . In this study, our data have shown that mPGES-1 signaling induces accumulation of EGR1 in human HCC cells. This observation is consistent with a previous study by Danesch et al. (1994) showing that PGE 2 increases EGR1 mRNA in 3T3 fibroblasts. Given that EGR1 can induce mPGES-1 gene expression through binding to the GC box region of the mPGES-1 gene promoter (Subbaramaiah et al., 2004; Moon et al., 2007; Ngiam et al., 2010) , it is conceivable that EGR1 and mPGES-1 may form a positive feedback loop that promotes tumorigenesis. A previous study has shown that EGR1 modulates b-catenin signaling pathway through upregulating the expression of TCF4 and p300 (Saegusa et al., 2008) . However, before the current study, it remains unknown whether these two transcription factors (EGR1 and b-catenin) might directly interact with each other in human cells. This study provides novel evidence for a direct interaction between EGR1 and b-catenin in human HCC cells. Our data showed that mPGES-1 overexpression increased nuclear b-catenin association with EGR1, whereas mPGES-1 knockdown decreased this interaction. Furthermore, EGR1 overexpression was found to enhance mPGES-1-induced b-catenin binding to TCF4/LEF1 proteins, as well as their association with TCF/LEF DNA consensus element, whereas EGR1 knockdown decreased these interactions. The observation that b-catenin knockdown prevents mPGES-1-induced EGR1 binding to LEF/ TCF DNA consensus site suggests that the effect of EGR1 is mediated through its association with b-catenin protein. Taken together, our findings reveal mPGES-1/ PGE 2 -induced activation of EGR1 and b-catenin in HCC cells.
The observation that SUMO-EGR1 did not bind b-catenin suggests that EGR1 sumoylation is probably not directly involved in mPGES-1-mediated b-catenin activation in HCC cells. However, given the reciprocal inverse correlation between EGR1 and SUMO-EGR1 in cells with altered mPGES-1 expression, it is possible that sumoylation of EGR1 may influence b-catenin activity by depleting the pool of non-sumoylated EGR1. In this context, it is interesting that GSK-3b overexpression increased sumoylated EGR1, but decreased non-sumoylated EGR1; these findings suggest that GSK-3b might inhibit b-catenin activity through sumoylation of EGR1, which leads to reduction of non-sumoylated EGR1. This viewpoint is corroborated by the observation that GSK3b overexpression partially inhibited mPGES-1-induced b-catenin association with TCF4 and EGR1.
In summary, this study shows that mPGES-1 and its enzymatic product, PGE 2 , inhibits GSK-3b and induces the formation of EGR1-b-catenin complex, which interacts with TCF4/LEF1 transcription factors, leading to b-catenin activation and upregulation of its downstream genes in human HCC cells (illustrated in Figure 11c ). The observation that b-catenin and EGR1 knockdown reverses mPGES-1 oncogenic potential demonstrates an important role of EGR1 and b-catenin in mPGES-1-induced HCC growth and progression. Our findings disclose a novel connection between mPGES-1/PGE 2 and EGR1/b-catenin signaling pathways, which are crucial for hepatocarcinogenesis. It is conceivable that these molecules may serve as important future therapeutic targets for effective chemoprevention and treatment of human HCC.
Materials and methods
Cell lines and plasmids
Human HCC cell lines (Hep3B and Huh7) were maintained in Minimum Essential Medium with Eagle's Salts from Invitrogen (Carlsbad, CA, USA) supplemented with 10% heatinactivated (56 1C, 30 min) fetal bovine serum (Sigma, St Louis, MO, USA) in a humidified atmosphere of 5% CO 2 incubator at 37 1C. Plasmids purchased from Origene (Rockville, MD, USA) are pCMV6-AC-GFP control vector, pCMV6-AV-GFP-mPGES-1, pGFP-V-RS control vector, pGFP-V-RS-mPGES-1, pGFP-V-RS-b-catenin, pGFP-V-RS-EGR1, pCMV5 control vector, pCMV5-b-catenin, pCMV5-EGR1 and pCMV5-mPGES-1.
Transfection and stable cell lines
Hep3B and Huh7 cells were transfected with pCMV6-AV-GFP-mPGES-1 overexpression plasmid, pCMV6-AC-GFP control vector, pGFP-V-RS-mPGES-1 knockdown plasmid, or pGFP-V-RS control vector, using Lipofectamine 2000 (Invitrogen). Stable cell lines were selected by culturing the transfected cells with a medium containing 1-2 mg/ml G418 (Calbiochem (EMD Chemical), Gibbstown, NJ, USA) for mPGES-1 overexpression or 1-2 mg/ml Puromycin (Invitrogen) for mPGES-1 knockdown. The selective media were replaced every 3 days. Distinct colonies of surviving cells were transferred onto 96-well plates and the cultures continued to grow in selection media. Transfection efficiency was measured by immunofluorescence staining and western blot using anti-GFP or anti-mPGES-1.
Cell proliferation WST assay
The cell proliferation was determined by using the cell proliferation reagent WST-1 (Roche, Indianapolis, IN, USA).
In brief, cells at a concentration 4 Â 10 3 were seeded into 96-well plates in 100 ml culture medium containing 10% fetal bovine serum to allow the cell re-attachment. The cells were then synchronized in G0 phase by serum deprivation and then released from growth arrest by re-exposure to serum for the assay. The cell proliferation reagent WST-1 was added to each well (10 mg/well), and the cells were incubated for up to 4 h at 37 1C and 5% CO 2 . OD450 was measured with an enzymelinked immunosorbent assay reader. Each sample was assayed in triplicates at daily intervals after seeding for up to 6 days. PGE 2 assay, enzyme immunoassay (EIA) was performed to determine the level of PGE 2 by using the Amersham PGE 2 biotrak EIA system (GE Healthcare, Piscataway, NJ, USA) according to the manufacturer's instructions.
Western blotting
At the end of each treatment, the cells were washed twice with ice-cold phosphate-buffered saline and then sonicated on ice in a lysis buffer (50 mM Tris-HCl, pH 8.0, containing 150 mM NaCl, 1% Nonidet P-40, 5 mM EDTA, with the protease inhibitor tablets from Roche, or together with 50 mM sodium fluoride, 25 mM glycerophosphate, or 1 mM Na 3 VO 4 for phosphorylation assay). Cell lysates were centrifuged at 12 000 g for 10 min at 4 1C, and the supernatants were collected for western blotting. Protein concentration was measured using a Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA). After boiling for 5 min in the loading buffer with 10% 2-mercaptoethanol, the samples containing 30 mg protein were separated on 10% Tris-glycine gels (Invitrogen); the separated proteins were transferred onto a nitrocellulose membrane (BioRad). Immunoblotting was performed using individual antibodies (including mouse monoclonal anti-mPGES-1, b-catenin, EGR1, SUM1 and biotin from Santa Cruz (Santa Cruz, CA, USA); b-actin from Sigma; rabbit polyclonal antiphospho-b-catenin, GSK-3b from Cell Signaling (Boston, MA, USA); histone from Abcam (San Francisco, CA, USA); and anti-TurboGFP from Evrogen (Moscow, Russia)).
Co-immunoprecipitation
For co-immunoprecipitation, the cells were lysed in 1 ml of the whole-cell extract buffer (50 mM pH 7.6 Tris-Cl, 150 mM NaCl, 0.5-1% Nonidet P-40, 0.1 mM EDTA, 1.0 mM DTT, with protease inhibitor tablets from Roche). A volume of 500 ml of total cell lysates was used in immunoprecipitation with indicated antibodies. In brief, cell lysates were pre-cleared with 30 ml protein G/A-plus agarose beads (Santa Cruz) by rotation for 1 h at 4 1C and the supernatant were obtained after centrifugation (1000 g) at 4 1C. The pre-cleared supernatant was incubated with 2 mg antibody by rotation for 4 h at 4 1C; the immunoprecipitates were then incubated with 30 ml protein G/A-plus agarose beads by rotation overnight at 4 1C. The precipitates were washed five times Â 10 min with beads wash solution (50 mM pH 7.6 Tris-Cl, 150 mM NaCl, 0.1% Nonidet P-40, 1 mM EDTA) and then resuspended in 40 ml 2 Â SDS-PAGE sample loading buffer for western blot with indicated antibodies.
DNA pulldown assay
Cells were lysed by sonication in HKMG buffer (10 mM HEPES, pH 7.9, 100 mM KCl, 5 mM MgCl 2 , 10% glycerol, 1 mM DTT and 0.5% Nonidet P-40) containing protease and phosphatase inhibitors for preparation of nuclear exacts. The nuclear extracts were pre-cleared with streptavidinagarose resin (Thermo Scientific, Pittsburgh, PA, USA) for 1 h, then the pre-cleared supernatant was incubated with 1 mg biotinylated double-stranded oligonucleotides TCF/LEF-site: mPGES-1 promotes HCC growth via activation of EGR1/b-catenin D Lu et al
